Multiple Myeloma Symptoms Are Generally Nonspecific
WEDNESDAY, July 19, 2023 -- Multiple myeloma (MM) symptoms are generally nonspecific, according to a study published online June 25 in Cancers.
Stella Bowcock, M.D., from the King ' s College Hospital NHS Trust in the United Kingdom, and colleagues... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 19, 2023 Category: Pharmaceuticals Source Type: news
Using Patient-Reported Outcomes to Measure Frailty in Patients with Multiple Myeloma
Frailty measures that use patient self-reports called “patient-reported outcomes” (PROs) can provide scientific information on a patient’s experience coming directly from patients. PROs can offer valuable information about a patient’s own health, quality of life, and functional capabilities, (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 11, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Woman shares her initial symptoms of 'incurable' blood cancer myeloma - 'I felt awful'
Sarah O'Fee experienced a niggling feeling that she was unwell back in 2009; unbeknown to her, she had cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - July 3, 2023 Category: Consumer Health News Source Type: news
PET/CT radiomics help with multiple myeloma prognosis
Radiomics models based on F-18 FDG-PET/CT imaging features and powered by machin...Read more on AuntMinnie.comRelated Reading:
SNMMI: Experts debate AI's role in nuclear medicine
PET/CT shows value in patients with portal vein thrombosis
SNMMI: PET tracer describes clear cell renal cancer
SNMMI: New technology improves whole-body PET image quality
PET predicts 'dry mouth' side effect in radiotherapy patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 30, 2023 Category: Radiology Source Type: news
K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)
Funds raised will be used to demonstrate clinical validation and proof-of-concept in t(4;14) multiple myeloma with KTX-1001 monotherapy and KTX-1001 combination regimens with existing standard-of-care agents
CAMBRIDGE, Mass., June 28, 2023 -- (Healthcar... Biopharmaceuticals, Oncology, Venture Capital K36 Therapeutics, MMSET, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2023 Category: Pharmaceuticals Source Type: news
The Future Of Cancer Treatment? Treating Multiple Myeloma With MRNA-CAR T Technology
The future of cancer treatment may involve two modern technologies: mRNA and CAR T Therapy. Here, we describe an example using multiple myeloma. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 27, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Clinical Advances in Multiple Myeloma From ASCO 2023 Clinical Advances in Multiple Myeloma From ASCO 2023
Improved outcomes using novel strategies and combination therapies in relapsed and severe disease highlight the multiple myeloma advances from ASCO 2023 chosen by Dr Jonathan Kaufman.Medscape (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 26, 2023 Category: Transplant Surgery Tags: Hematology-Oncology ReCAP Source Type: news
Blood cancer: Man almost paralysed by undiagnosed myeloma
For months Jamie Hart continued to work with no idea he had a collapsed vertebra. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - June 26, 2023 Category: Consumer Health News Source Type: news
Arcellx's cell therapy is on hold after patient death in multiple myeloma trial
Arcellx said its autologous cell therapy was put on hold last Friday after the death of a recent patient in a trial testing the biotech’s CAR-modified T cell therapy in relapsed or refractory multiple myeloma. The hold impacts Arcellx’s lead program, which is also part…#gilead #kite #unlock (Source: Reuters: Health)
Source: Reuters: Health - June 20, 2023 Category: Consumer Health News Source Type: news
Multiple myeloma has long been a killer. Therapies are changing that.
New drugs have made it possible to live much longer with the disease, and some scientists even see a possible cure down the road. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - June 20, 2023 Category: Consumer Health News Authors: Marlene Cimons Source Type: news
ASCO: Cilta-Cel Beneficial for Lenalidomide-Refractory Multiple Myeloma
THURSDAY, June 8, 2023 -- For patients with lenalidomide-refractory multiple myeloma, a single cilta-cel infusion results in lower risk of disease progression or death compared with standard care, according to a study published online June 5 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 8, 2023 Category: Pharmaceuticals Source Type: news
CAR T-Cell Benefit in Lenalidomide-Refractory Myeloma CAR T-Cell Benefit in Lenalidomide-Refractory Myeloma
The CAR T-cell construct was associated with significantly better progression-free survival than standard-of-care multidrug regimens.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 6, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Genetically modifying T-cells cuts blood cancer progression by 74%, trial finds
A revolutionary blood cancer treatment that genetically modifies patient cells to fight the disease cuts the risk of it progressing by 74%, a world-first clinical trial has found. The therapy, ciltacabtagene autoleucel, “significantly slows or stops progression” of multiple myeloma in patients who…#carvykti #lenalidomide #oreofeodejide #drbinoddhakal #milwaukee (Source: Reuters: Health)
Source: Reuters: Health - June 5, 2023 Category: Consumer Health News Source Type: news
New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials
(MedPage Today) -- CHICAGO -- More than 70% of patients with heavily pretreated multiple myeloma had responses to the novel bispecific antibody talquetamab plus subcutaneous daratumumab (Darzalex Faspro), a preliminary trial showed.
The higher... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2023 Category: Hematology Source Type: news
CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma
(MedPage Today) -- CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) reduced the risk of disease progression or death compared with standard care in lenalidomide... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2023 Category: Hematology Source Type: news
